Related Experiment Videos
Isolation of a colon tumor specific binding peptide using phage display selection
Kimberly A Kelly1, David A Jones
1Huntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City, UT 84112, USA.
Neoplasia (New York, N.Y.)
|December 13, 2003
Summary
Researchers developed a new peptide, RPMrel, using phage display to detect colon cancer tissues. This peptide shows promise for early colorectal cancer diagnosis and targeted drug delivery, binding specifically to tumor cells without affecting normal tissues.
Area of Science:
- Oncology
- Biotechnology
- Molecular Biology
Background:
- Colorectal cancer is a leading cause of cancer-related deaths in the US.
- Early detection of colorectal neoplasms is crucial for improving patient outcomes.
- Novel diagnostic and therapeutic strategies are needed for colon carcinoma.
Purpose of the Study:
- To develop a peptide-based tool for detecting colon carcinoma tissues.
- To identify a peptide that specifically targets colon tumor cells.
- To explore the potential of this peptide for targeted drug delivery.
Main Methods:
- Phage display technology was utilized to generate and select peptide libraries.
- Positive selection was performed on HT29 (poorly differentiated) colon carcinoma cells.
- Negative selection was performed on HCT116 (well-differentiated) colon carcinoma cells.
- Immunohistochemistry was used to validate peptide binding to tumor tissues.
Main Results:
- A nine-amino-acid peptide, RPMrel, was identified that specifically stains HT29 colon carcinoma cells.
- RPMrel demonstrated binding to colon tumor tissues from patients but not to normal colon tissues.
- The peptide did not bind to non-colon tissues such as lungs, liver, and stomach.
- RPMrel conjugated to a mitochondrial toxin effectively killed HT29 cells.
Conclusions:
- RPMrel is a promising candidate for the development of colon tumor diagnostics.
- The peptide shows potential as a targeted drug delivery agent for colon cancer.
- Further research is warranted to explore its clinical applications.